Comments
Aurobindo Pharma Ltd’s net profit increased 4.6 per cent at ₹640 crore in the second quarter ended September 30, 2019 compared to ₹611 crore in the corresponding quarter of the previous year.
The total revenue of the Hyderabad based company increased 17.9 per cent at ₹5,600 crore against ₹4,751 crore.
“We had a quarter of healthy performance where we continued to grow in US and Europe, which are our focused geographies. Our R&D initiatives have been progressing well across the products basket and we have started clinical trials for our first biosimilar product in Q3FY20,’’ N. Govindarajan, Managing Director, Aurobindo Pharma said in a release.
The company was in the process of resolving all pending regulatory issues, he added.
Revenue from US formulations increased 27.3 per cent at ₹2,835.5 crore (₹2,227 crore). Europe formulations revenue stood at ₹1,401 cr, which is an increase of 21.2 per cent against last year. Growth Markets posted a growth of 3.8 per cent.
Research & Development (R&D) spend was at Rs 223 cr, amounting to 4 pc of revenues Basic and diluted EPS is Rs 10.92 per share.
Aurobindo’s board approved an Interim Dividend at 125 per cent for ₹1.25 per equity share of Re. 1/- each on the equity share capital of the company for the Financial Year 2019-20.
Aurobindo’s scrip gained 2.58 per cent after opening of trade on the Bombay Stock Exchange on Wednesday.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.